Icon Bioscience
Sunnyvale
About Icon Bioscience
IBI is developing a broad portfolio of clinically superior proprietary products, based on its Verisome® drug delivery technology. The company’s initial focus is on its pipeline of reduced-risk, low-cost development programs targeting every major ophthalmic market. IBI’s lead portfolio product, IBI-10090 completed enrollment in its pivotal phase 2/3 clinical trial, in December 2012. An NDA is planned for late 2013. It was founded in 2004 and headquartered in Sunnyvale, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $37.3M
- Funding stage: M&A
- Last round: Convertible Note (Dec 2015)
- Website: iconbioscience.com
- Phone: 650-369-4049
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/icon-bioscience-2728087 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.